Article Details

Experimental Pfizer Arthritis Drug Too Risky: FDA Panel

Retrieved on: 2021-03-26 21:45:00

Tags for this article:

Click the tags to see associated articles and topics

Experimental Pfizer Arthritis Drug Too Risky: FDA Panel. View article details on hiswai:

Excerpt

FRIDAY, March 26, 2021 (HealthDay News) -- The Pfizer experimental arthritis drug tanezumab is too risky to approve, a U.S. Food and Drug ...

Article found on: consumer.healthday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up